Cost Is the Biggest Barrier to Breyna Adherence — Here's How to Help

You've prescribed Breyna (Budesonide/Formoterol Fumarate Dihydrate) because it's the right medication for your patient's asthma or COPD. But if they can't afford to fill it, the prescription is just a piece of paper. Cost-related non-adherence is one of the most common reasons patients with chronic respiratory disease have poor outcomes — and it's one of the most preventable.

This guide breaks down every savings option available for Breyna in 2026, so you and your staff can quickly match patients to the right program and keep them on therapy.

What Patients Are Actually Paying

Understanding the real-world cost landscape helps you anticipate which patients will struggle and proactively offer solutions.

Cash Prices (No Insurance)

• Breyna 80/4.5 mcg (120 inhalations): $280–$350 per inhaler
• Breyna 160/4.5 mcg (120 inhalations): $350–$472 per inhaler

For a patient using one inhaler per month, that's $3,360 to $5,664 per year at full cash price. Even patients who can technically afford it may balk at these numbers, leading to rationing, skipped doses, or outright abandonment of therapy.

With Insurance

Most commercial plans and Medicare Part D formularies cover Breyna, typically on a preferred generic tier. However:

• Copays range from $10–$75 depending on the plan and tier
• Some plans require prior authorization or step therapy (trial of an ICS alone first)
• High-deductible health plans may require patients to pay full price until their deductible is met — which for Breyna can mean several hundred dollars per fill early in the year

With Discount Cards

For uninsured or underinsured patients, prescription discount cards significantly reduce out-of-pocket costs:

• GoodRx: approximately $155–$215 per inhaler
• SingleCare: approximately $155–$160 per inhaler
• RxSaver, Optum Perks, BuzzRx: similar range, varies by pharmacy

These cards are free, require no sign-up, and can be used at most pharmacies. They're the fastest intervention for patients facing high out-of-pocket costs.

Manufacturer Savings Programs

Viatris Breyna Savings Card

This is the primary manufacturer-sponsored program for Breyna:

• Eligibility: Commercially insured patients (private insurance, employer plans)
• Benefit: Pay as little as $20 per monthly fill
• Annual maximum: $360 in savings per calendar year
• Enrollment: Patients can register and download the card at activatethecard.com or through their pharmacy

Key limitations:

• Not valid for government-insured patients: Medicare, Medicaid, Tricare, VA, or state pharmaceutical assistance programs
• Does not apply to uninsured patients (they should use discount cards or the PAP instead)
• Subject to change or discontinuation by Viatris

Clinical workflow tip: Have your front desk or medical assistants proactively mention the savings card when Breyna is prescribed. Better yet, include the enrollment link in your after-visit summary or patient portal message. The less friction, the more likely patients will actually use it.

AstraZeneca Symbicort Savings

For patients who need brand-name Symbicort specifically (identical active ingredients to Breyna), AstraZeneca has capped out-of-pocket costs at $35/month for many commercially insured patients. This is worth knowing if a patient's insurance covers Symbicort but not Breyna, or if the patient has a preference.

Patient Assistance Programs (PAPs)

For patients who are uninsured, underinsured, or experiencing financial hardship, patient assistance programs provide Breyna at no cost.

Viatris Patient Assistance Program

• Eligibility: Uninsured or underinsured patients with demonstrated financial need (income guidelines apply)
• Benefit: Breyna provided free of charge
• How to apply: Complete an application at viatris.com or call 888-417-5780
• Requirements: Completed application form, proof of income documentation, valid prescription
• Processing time: Typically 2–4 weeks; plan ahead so patients don't run out of medication during the application period

Clinical workflow tip: Keep PAP application forms in your office or have the URL bookmarked for easy access. For patients who qualify, start the application during the office visit — hand them the form, help them understand what documentation they need, and note in the chart that a PAP application is in progress. Consider providing a 30-day bridge supply (samples if available, or a discount card) while the application is processed.

Additional Resources

• NeedyMeds — searchable database of patient assistance programs, including Budesonide/Formoterol options
• RxAssist — comprehensive directory of PAPs with application guidance
• State pharmaceutical assistance programs — many states offer additional programs for residents who don't qualify for Medicaid but can't afford medications

Generic Alternatives and Therapeutic Substitution

When cost is the primary barrier, switching to a more affordable medication in the same class may be the most practical solution.

Within the Same Drug

Breyna is the generic option for Budesonide/Formoterol. If your patient is currently on brand-name Symbicort, switching to Breyna can save $70–$200+ per fill depending on the pharmacy and discount used. The medications are therapeutically equivalent and FDA-approved as interchangeable.

Alternative ICS/LABA Combinations

• Generic Advair (Fluticasone/Salmeterol): Often the most affordable ICS/LABA option, with discount card prices as low as $50–$150. Different active ingredients but same drug class. Onset is slower (Salmeterol takes 15–30 minutes vs. Formoterol's 1–3 minutes).
• Breo Ellipta (Fluticasone/Vilanterol): Once-daily dosing may improve adherence. Brand-only, so price is higher, but manufacturer coupons are available. Adults only (not approved for pediatric asthma).
• Dulera (Mometasone/Formoterol): Brand-only, typically more expensive. Same LABA (Formoterol) as Breyna but different ICS. Limited cost advantage.

When to consider switching:

• Patient cannot afford Breyna even with all available discounts
• Insurance formulary strongly favors a different ICS/LABA
• Patient has tried Breyna and has tolerability issues (switching ICS component may help)

When to keep Breyna:

• Patient is well-controlled and adherent — don't fix what isn't broken
• Formoterol's fast onset is clinically important for the patient
• Patient has tried Fluticasone-based alternatives and had side effects

Building Cost Conversations Into Your Workflow

The most effective savings program is useless if your patient doesn't know about it. Here are practical strategies for integrating cost discussions into routine care.

Normalize the Conversation

Many patients won't volunteer that they can't afford their medication — they'll just stop taking it. Ask directly:

• "Do you have any concerns about the cost of this medication?"
• "Are you able to fill your prescriptions without difficulty?"
• "Have you ever skipped doses or stretched your inhaler because of cost?"

These questions should be as routine as checking vitals.

Use the Prescribing Moment

The best time to address cost is when you write the prescription. At that point:

1. Check formulary status — use your EHR's formulary lookup or call the patient's insurance to confirm coverage and tier
2. Mention the savings card — for commercially insured patients, proactively provide the Viatris Savings Card information
3. Offer a discount card — for uninsured patients, recommend GoodRx or SingleCare and suggest they compare pharmacy prices
4. Start the PAP process — for patients with financial hardship, initiate the application during the visit

Delegate to Your Team

Cost navigation doesn't have to fall on the prescriber. Train your:

• Medical assistants to ask about medication affordability during intake
• Front desk staff to hand out savings card information with new prescriptions
• Care coordinators or social workers to manage PAP applications and follow up on coverage issues
• Pharmacist partners to run discount card comparisons and alert you to prior authorization requirements

Document and Follow Up

Note in the chart which savings program the patient is using and set a reminder to check adherence at the next visit. If a patient reports stopping Breyna, cost should be one of the first things you explore.

Tools for Providers

Several resources can streamline the savings process for your practice:

• Medfinder for Providers — helps locate pharmacies with Breyna in stock and connects patients with availability information
• GoodRx for Providers — free tool to look up discount prices and send coupons directly to patients
• EHR-integrated formulary tools — most major EHRs (Epic, Cerner, Athena) have built-in formulary checkers that flag coverage issues at the point of prescribing
• Manufacturer websites — Viatris maintains updated program information and downloadable materials for providers

Final Thoughts

Breyna is an effective, evidence-based therapy for asthma and COPD — but only if patients can afford to take it consistently. By building cost conversations into your workflow and connecting patients to the right savings programs, you can significantly improve adherence and outcomes.

The good news: between the Viatris Savings Card ($20/month for commercially insured patients), discount cards ($155–$280 per inhaler), and the patient assistance program (free for qualifying patients), there's a path to affordability for nearly every patient. Your role is to make sure they find it.

For more clinical resources, visit Medfinder for Providers. For patient-facing guides to share, see our articles on saving money on Breyna and finding Breyna in stock.